ロード中...
Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)
BACKGROUND: Three classes of inhaler medications are used to manage chronic obstructive pulmonary disease (COPD): long‐acting beta‐agonists (LABA), long‐acting muscarinic antagonists (LAMA), and inhaled corticosteroids (ICS). When two classes of medications are required, LAMA plus LABA (LAMA+LABA) a...
保存先:
| 出版年: | Cochrane Database Syst Rev |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Ltd
2017
|
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6464543/ https://ncbi.nlm.nih.gov/pubmed/28185242 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012066.pub2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|